Work

366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.10.359

Authors: S-W. Kim, D. Planchard, P-H. Feng, N. Karaseva, T.M. Kim, C.K. Lee, A. Poltoratskiy, N. Yanagitani, S. Powar, X. Huang, P. Howarth, P. Jänne, K. Kobayashi

Institutions: Asan Medical Center, Institut Gustave Roussy, Fondation Gustave Roussy, Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, City Clinical Oncology Center, Seoul National University, Seoul National University Hospital, St George Hospital, Institute of Oncology NN Petrov, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute, Saitama Medical University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, AstraZeneca France

OpenAlex ID: W4253948707

FWCI: 0.123

Cites:

Cited by: 1

Related to: 10